Adjuvant hormonal therapy in premenopausal women with operable breast cancer: Not-so-peripheral perspectives

ONCOLOGY

Volumn 24, Issue 4, 2010, Pages

  Love, Richard R ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b International Breast Cancer Research Foundation   (United States)

^c Amader Gram Breast Care Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN; GONADORELIN AGONIST; METHOTREXATE; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER SURVIVAL; COST OF ILLNESS; DRUG CLEARANCE; DRUG METABOLISM; GENOTYPE; HUMAN; MASTECTOMY; MEDICAL ETHICS; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; PARTIAL MASTECTOMY; PHARMACOGENETICS; PREMENOPAUSE; REVIEW;

EID: 77952030203     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Ramo JC: The age of the unthinkable, p 11. New York; Little, Brown; 2009.
2. Pritchard KI: Ovarian supprerssion/ablation in premenopausal ER-positive breast cancer patients: Issues and recommendations. Oncology (Williston Park) 23:27-47 (incl discussion), 2009.
3. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no 5, version 2.0. Lyon, France; IARC Press; 2004.
4. Curado MP, Edwards B, Shin HR, et al (eds): Cancer incidence in five continents, vol IX. IARC scientific publications no. 160. Lyon, France; IARC Press; 2007.
5. Love RR: Defining a global research agenda for breast cancer. Cancer 113:2366-2371, 2008.
6. Olopade F, Grushko TA, Nanda R, et al: Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 14:7988-7999, 2008.
7. Tan S-H, Lee S-C, Goh B-C, et al: Pharmacogenetics in breast cancer therapy. Clin Cancer Res 14:8027-8041, 2008.
8. Uy GB, Laudico AV, Fernandez AM, et al: Immunohistochemical assay of hormone receptors in breast cancer at The Philippine General Hospital: Importance of early fixation of specimens. Philipp J Surg Spec 62:123-127, 2007.
9. Shen Y-C, Change C-J, Hsu C, et al: Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications for age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 14:1986-1990, 2005.
10. Goldstein NS, Hewitt SM, Taylor CR, et al: Recommendations for improved standardization of immunohistochemistry. App Immunohistochem Mol Morphol 15:124-133, 2007.
11. Werner M, Chott A, Fabiano A, et al: Effect of formalin tissue fixation and processing in immunohistochemistry. Am J Surg Pathol 24:1016-1019, 2000.
12. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Path 120:86-92, 2003.
13. Mann GB, Fahey VD, Feleppa F, et al: Reliance on hormone receptor assay of surgical specimens may compromise outcomes in patients with breast cancer. J Clin Oncol 23:5148-5154, 2005.
14. Uy GB, Laudico AV, Carnate JM, et al: Breast cancer hormone receptor assay results from core needle biopsy and modified radical mastectomy specimens from the same patients. Clin Breast Cancer 10(2), 2010.
15. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
16. Saphner T, Tormey DC, Gray R: Annual hazard rates recurrence for breast cancer afterprimary therapy. J Clin Oncol 14:2738-2746, 1996.
17. Goss PE, Ingle JN, Pater JL: Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer completing 5 years of tamoxifen. J Clin Oncol 26:1948-1955, 2008.
18. Hess KR, Pusztai L, Budzar AU, et al: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118, 2003.
19. Love RR, Dinh NV, Quy TT, et al: Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.J Clin Oncol 26:253-257, 2008.
20. Mamounas EP, Jeong J-H, Wickerham DL, et al: Benefit from exemestane as extended adjuvant therapy following five years of adjuvant tamoxifen. J Clin Oncol 26:1965-1971, 2008.
21. Gray RG, Rea DW, Handley A, et al: aTTom (adjuvant TamoxifenTo offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancerpreliminary results (abstract 513). J Clin Oncol 26(15S):10s, 2008.
22. Peto R, Davies C: ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women. Preliminary results. Late breaking abstract presentation. San Antoinio Breast Cancer Symposium; San Antonio, Texas; December 14, 2007.
23. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009.
24. Klijn JG, Beex LV, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000.
25. Klijn JG, Blamey RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone (LHRH) agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001.
26. Davidson NE, ONeill AM, Vukov AM, et al: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer. Results from INT 0101 (E5188). J Clin Oncol 23:5973-5982, 2005.
27. Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic brerast cancer. J Clin Oncol 16:3439-3460, 1998.
28. Cusick J, Ambroisine L, Davidson N, et al: Use of luteinising hormone releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor positive breast cancer: A meta-analysis of individual patient data from randomized adjuvant trials. Lancet 369:1711-1723, 2007.
29. Robert NJ, Wang M, Cella D, et al: Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer d 3 cm (abstract 16). Proc Am Soc Clin Oncol 22:5, 2003.
30. Jakecz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserilin versus cyclophosphamide, methotrexate, and fluoruracil: evidence for the superiority of treatment with endocrine blcoikagde in premenopausal patients with hormone responsive breast cancer. J Clin Oncol 20:4621-4627, 2002.
31. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and flurouracil as adjuvant therapy in premenopausal women with node positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002.
32. Jordan VC, Collins MM, Rowsby L, et al: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316, 1977.
33. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:758-1764, 2003.
34. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004.
35. Desta Z, Flockhart DA: Germline pharmacogenetics of tamoxifen response: Have we learned enough? J Clin Oncol 25:5147-5149, 2007.
36. Desta Z, Ward BA, Soukhova NV, et al: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075, 2004.
37. Jin Y, Desta Z, Stearns V, et al:CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.J Natl Cancer Inst 97:30-39, 2005.
38. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006.
39. Sun D, Sharma AK, Dellinger RW, et al: Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35:2006-2014, 2007.
40. Blevins-Primeau AS, Sun D, Chen G, et al: Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69:1892-1900, 2009.
41. Tan S-H, Lee S-C, Goh B-C, et al: Pharmacogenetics in breast cancer therapy. Clin Cancer Res 24:8027-8041, 2008.
42. Dezentjé VO, Guchelaar HJ, Nortier JW, et al: Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15-21, 2009.
43. Hayes DF, Stearns V, Rae J, et al: A model citizen? Is tamoxifen more effective than aromatase inhibitor if we pick the right patients? J Natl Cancer Inst 100:610-613, 2008.
44. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005.
45. Goetz MP, Knox SK, Suman VJ, et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007.
46. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007.
47. Gonzales-Santiago S, Zarate R, Haba-Rodriguez J, et al: CYP2D6*4 polymorphisms as a blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. (abstract 590) J Clin Oncol 25(18S):25s, 2007.
48. Kiyotani K, Mushiroda T, Sas M, et al: Impact of CYP2D6*10 on recurrence free survival in breast cancer patientsreceiving adjuvant tamoxifen therapy. Cancer Sci 99:995-999, 2008.
49. Xu Y, Sun Y, Yao L, et al: Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423-1429, 2008.
50. Lim HS, Ju LH, Seok LK, et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharamacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845, 2007.
51. Bonanni B, Macis D, Maisonneuve P, et al: Polymorphism in the CYP2D6 tamoxifen metabolizing gene influences clinical effect but not hot flashes: Data from the Italian Tamoxifen Trial.J Clin Oncol 24:3708-3709, 2006.
52. Nowell SA, Ahn J, Rae JM, et al: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258, 2005.
53. Wegman P, Vainikka L, Stal O, et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 7:R284-R290, 2005.
54. Wegman P, Elingarami S, Carstensen J, et al: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res Treat 9:R7, 2007.
55. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized climnical trial of goserilin versus surgical oophorectomy in premenopausal patients with receptor positive metastatic brast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998.
56. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserilin with or without tamoxifen in pre-menopausal patientsd with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994.
57. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15, 71-85, 1992.
58. Retsky MW, Demicheli R, Swartzendruber DE, et al: Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 45:193-202, 1997.
59. Love RR, Duc NB, Dinh NV, et al: Mastectomy and oophorectomy by menstrual cycle phase in operable breast cancer. J Natl Cancer Inst 94:662-669, 2002.
60. Love RR, Young GS, Hade EM, et al: Timing of adjuvant surgical oophorectomy in the menstrual cycle of premenopausal women with breast cancer and survival. Cancer. In press.
61. Love RR, Niederhuber JN: Models of breast cancer growth and investigations of adjuvant oophorectomy. Ann Surg Oncol 11:818-828, 2004.
62. Lee J-W, Shazad MMK, Lin YG, et al: Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15:2695-2702, 2009.